Impact of socio-economic factors on the long-term effectiveness of antihypertensive treatment with an angiotensin II receptor blocker: an observational study

References

• Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011;377:568-77
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Mancia G. 2013 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-57
   PubMed Web of Science ®Google Scholar
• Mayer O Jr, Simon J, Heidrich J, et al. Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health 2004;58:47-52
   PubMed Web of Science ®Google Scholar
• Rutledge T, Reis SE, Olson M, et al. Socioeconomic status variables predict cardiovascular disease risk factors and prospective mortality risk among women with chest pain. The WISE Study. Behavior Modification 2003;27:54-67
   PubMed Web of Science ®Google Scholar
• Bachmann MO, Eachus J, Hopper CD, et al. Socio-economic inequalities in diabetes complications, control, attitudes and health service use: a cross-sectional study. Diabetic Med 2003;20:921-9
   PubMed Web of Science ®Google Scholar
• Schneider S, Mohnen S, Schiltenwolf M. [‘Are rich people healthier?' – Representative epidemiological data on socioeconomic group-specific disease prevalences among adults in Germany]. [German]. Deutsche Medizinische Wochenschrift 2006;131:1998-2003
   Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Bramlage P, Lichtenthal A, et al. Socio-economic status and the therapeutic effectiveness of antihypertensive treatment – the design of the LEO study. Curr Med Res Opin 2007;23:1987-95
   PubMed Web of Science ®Google Scholar
• Oparil S, Williams D, Chysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91
   PubMedGoogle Scholar
• Brunner HR. Clinical efficacy and tolerability of olmesartan. Curr Therapeut 2004;26:A28-32
   PubMed Web of Science ®Google Scholar
• Scholze J, Schaefer A, Kreutz, R. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients. Expert Opin Drug Saf 2011;10:185-96
   PubMed Web of Science ®Google Scholar
• Mathes J, Kostev K, Gabiel A, et al. Relation of the first hypertension-associated event with medication, compliance and persistence in naive hypertensive patients after initiating monotherapy. Int J Clin Pharmacol Therapeut 2010;48:173-83
   PubMed Web of Science ®Google Scholar
• Fabia MJ, Abdilla N, Oltra R, et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-36
   PubMed Web of Science ®Google Scholar
• Zannad F, Fay R. Blood pressure lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists. An overview of randomized controlled studies. Fundam Clin Pharmacol 2007;21:181-90
   PubMed Web of Science ®Google Scholar
• Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig 2007;27:545-58
   PubMed Web of Science ®Google Scholar
• Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004–2006. Med J Aust 2008;188:224-7
   PubMed Web of Science ®Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Human Hypertens 2002;16:569-75
   PubMed Web of Science ®Google Scholar
• Böhm M, Schmumacher H, Laufs U, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013;166:306-14
   PubMed Web of Science ®Google Scholar